

Specialty Drug Management List

Coverage for Specialty Medications

The Specialty Drug Management List is a list of medications that our plans identify as being a specialty medication. Specialty medications are often prescribed to treat complex and/or chronic conditions, such as multiple sclerosis, hepatitis C and rheumatoid arthritis. These medications may have special handling and/or storage needs. Coverage for specialty medications that are FDA approved for *self-administration* are often provided through your *pharmacy* benefit plan. Specialty medications that are FDA approved for administration by a health care professional are often covered under your *medical* benefit plan. Some medications on the Specialty Drug Management List may be covered by either the pharmacy or medical benefit. So, these medications will appear under both the pharmacy and medical sections. The Specialty Drug Management List is not all inclusive and is subject to change. The listing of the drug on this list does not guarantee coverage. If you have any questions, call the number on your member ID card.

Drugs Covered Under Your Pharmacy Benefits:

Please note: You may need approval before these drugs can be considered for coverage. Your doctor can find request forms at bcbsil.com/provider. Your doctor can also call the number on your ID card with any questions about your benefits. Based on the terms of your benefit plan, you may need to fill these prescriptions at an in-network specialty pharmacy to get the most out of your benefits. Call the number on your member ID card to help locate an in-network specialty pharmacy near you. BCBSIL members who use oral oncology or hemophilia specialty drugs may have other in-network specialty pharmacy options.

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|------------------------|-------------------------|
| ABIRATERONE ACETATE | CANCER-ORAL | OR |
| ACTEMRA | AUTOIMMUNE | SC |
| ACTEMRA ACTPEN | AUTOIMMUNE | SC |
| ACTHAR | ENDOCRINE | IJ |
| ACTIMMUNE | LUNG DISORDERS | SC |
| ADALIMUMAB-ADAZ | AUTOIMMUNE | SC |
| ADALIMUMAB-ADBIM | AUTOIMMUNE | SC |
| ADALIMUMAB-FKJP | AUTOIMMUNE | SC |
| ADBRY | AUTOIMMUNE | SC |
| ADCIRCA | PULMONARY HYPERTENSION | OR |
| ADEMPAS | PULMONARY HYPERTENSION | OR |
| ADVATE | HEMOPHILIA | IV |
| ADYNOVATE | HEMOPHILIA | IV |
| AFINITOR | CANCER-ORAL | OR |
| AFINITOR DISPERZ | CANCER-ORAL | OR |
| AFSTYLA | HEMOPHILIA | IV |
| ALECENSA | CANCER-ORAL | OR |
| ALKERAN | CANCER-ORAL | OR |
| ALKINDI SPRINKLE | CORTICOSTEROIDS | OR |
| ALPHANATE | HEMOPHILIA | IV |
| ALPHANINE SD | HEMOPHILIA | IV |
| ALPROLIX | HEMOPHILIA | IV |
| ALTUVIIO | HEMOPHILIA | IV |
| ALUNBRIG | CANCER-ORAL | OR |
| ALYQ | PULMONARY HYPERTENSION | OR |
| AMBRISENTAN | PULMONARY HYPERTENSION | OR |
| AMJEVITA | AUTOIMMUNE | SC |
| AMPYRA | MULTIPLE SCLEROSIS | OR |
| APOKYN | PARKINSON | SC |
| A POMORPHINE | PARKINSON | SC |
| ARANESP ALBUMIN FREE | BLOOD MODIFIERS | IJ |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|------------------------|-------------------------|
| ARCALYST | AUTOIMMUNE | SC |
| ARIKAYCE | OTHER NON-CATEGORIZED | IN |
| AUBAGIO | MULTIPLE SCLEROSIS | OR |
| AUSTEDO | OTHER NON-CATEGORIZED | OR |
| AVONEX PEN | MULTIPLE SCLEROSIS | IM |
| AVONEX PREFL | MULTIPLE SCLEROSIS | IM |
| AYVAKIT | CANCER-ORAL | OR |
| BAFIERTAM | MULTIPLE SCLEROSIS | OR |
| BALVERSA | CANCER-ORAL | OR |
| BENEFIX | HEMOPHILIA | IV |
| BENLYSTA | AUTOIMMUNE | SC |
| BERINERT | HEMATOLOGICAL | IV |
| BESREMI | CANCER | SC |
| BETAINE ANHYDROUS | ENZYME DEFICIENCIES | OR |
| BETASERON | MULTIPLE SCLEROSIS | SC |
| BETHKIS | CYSTIC FIBROSIS | IN |
| BEXAROTENE | CANCER-ORAL | OR |
| BEXAROTENE | CANCER | EX |
| BOSENTAN | PULMONARY HYPERTENSION | OR |
| BOSULIF | CANCER-ORAL | OR |
| BRAFTOVI | CANCER-ORAL | OR |
| BRONCHITOL | CYSTIC FIBROSIS | IN |
| BRONCHITOL TOLERANCE TEST | CYSTIC FIBROSIS | IN |
| BRUKINSA | CANCER-ORAL | OR |
| BUPHENYL | ENZYME DEFICIENCIES | OR |
| BYLVAY | OTHER NON-CATEGORIZED | OR |
| CABLIVI | BLOOD MODIFIERS | IJ |
| CABOMETYX | CANCER-ORAL | OR |
| CALQUENCE | CANCER-ORAL | OR |
| CAMZYOS | OTHER NON-CATEGORIZED | OR |
| CAPECITABINE | CANCER-ORAL | OR |
| CAPRELSA | CANCER-ORAL | OR |
| CARBAGLU | ENZYME DEFICIENCIES | OR |
| CARGLUMIC | ENZYME DEFICIENCIES | OR |
| CASODEX | CANCER-ORAL | OR |
| CAYSTON | CYSTIC FIBROSIS | IN |
| CERDELGA | ENZYME DEFICIENCIES | OR |
| CETRORELIX | FERTILITY & PREGNANCY | SC |
| CETROTIDE | FERTILITY & PREGNANCY | SC |
| CHENODAL | GASTROINTESTINAL | OR |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|------------------------|-------------------------|
| CHOLBAM | GASTROINTESTINAL | OR |
| CHORIONIC GONADOTROPIN | FERTILITY & PREGNANCY | IM |
| CIBINQO | AUTOIMMUNE | OR |
| CIMZIA | AUTOIMMUNE | SC |
| CIMZIA STARTER KIT | AUTOIMMUNE | SC |
| CLOVIQUE | OTHER NON-CATEGORIZED | OR |
| COAGADEX | HEMOPHILIA | IV |
| COMETRIQ | CANCER-ORAL | OR |
| COPAXONE | MULTIPLE SCLEROSIS | SC |
| COPIKTRA | CANCER-ORAL | OR |
| CORIFACT | HEMOPHILIA | IV |
| CORTROPHIN | ENDOCRINE | IJ |
| COSENTYX | AUTOIMMUNE | SC |
| COSENTYX SENSOREADY PEN | AUTOIMMUNE | SC |
| COSENTYX UNOREADY | AUTOIMMUNE | SC |
| COTELLIC | CANCER-ORAL | OR |
| CUPRIMINE | OTHER NON-CATEGORIZED | OR |
| CUVRIOR | OTHER NON-CATEGORIZED | OR |
| CYLTEZO | AUTOIMMUNE | SC |
| CYSTADANE | ENZYME DEFICIENCIES | OR |
| CYSTADROPS | OPHTHALMIC | OP |
| CYSTAGON | OTHER NON-CATEGORIZED | OR |
| CYSTARAN | OPHTHALMIC | OP |
| DALFAMPRIDINE ER | MULTIPLE SCLEROSIS | OR |
| DAURISMO | CANCER-ORAL | OR |
| DAYBUE | OTHER NON-CATEGORIZED | OR |
| DEFERASIROX | OTHER NON-CATEGORIZED | OR |
| DEFERIPRONE | OTHER NON-CATEGORIZED | OR |
| DEPEN TITRATABS | OTHER NON-CATEGORIZED | OR |
| DIMETHYL FUMARATE | MULTIPLE SCLEROSIS | OR |
| DIMETHYL FUMARATE STARTERPACK | MULTIPLE SCLEROSIS | OR |
| DOJOLVI | VITAMINS & SUPPLEMENTS | OR |
| DOPTELET | BLOOD MODIFIERS | OR |
| DUPIXENT | AUTOIMMUNE | SC |
| EGRIFTA SV | HIV | SC |
| ELIGARD | CANCER-ORAL | SC |
| ELOCTATE | HEMOPHILIA | IV |
| EMCYT | CANCER-ORAL | OR |
| EMFLAZA | CORTICOSTEROIDS | OR |
| EMPAVELI | HEMATOLOGICAL | SC |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.



Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|-----------------------|-------------------------|
| ENBREL | AUTOIMMUNE | SC |
| ENBREL MINI | AUTOIMMUNE | SC |
| ENBREL SURECLICK | AUTOIMMUNE | SC |
| ENDARI | BLOOD MODIFIERS | OR |
| ENSPRYNG | IMMUNOSUPPRESSANTS | SC |
| EPCLUSA | HEPATITIS C | OR |
| EPOGEN | BLOOD MODIFIERS | IJ |
| ERIVEDGE | CANCER-ORAL | OR |
| ERLEADA | CANCER-ORAL | OR |
| ERLOTINIB HYDROCHLORIDE | CANCER-ORAL | OR |
| ESBRIET | LUNG DISORDERS | OR |
| ESPEROCT | HEMOPHILIA | IV |
| ETOPOSIDE | CANCER-ORAL | OR |
| EULEXIN | CANCER | OR |
| EVEROLIMUS | CANCER-ORAL | OR |
| EVRYSDI | OTHER NON-CATEGORIZED | OR |
| EXJADE | OTHER NON-CATEGORIZED | OR |
| EXKIVITY | CANCER | OR |
| EXTAVIA | MULTIPLE SCLEROSIS | SC |
| FARESTON | CANCER-ORAL | OR |
| FASENRA PEN | LUNG DISORDERS | SC |
| FEIBA | HEMOPHILIA | IV |
| FERRIPROX | OTHER NON-CATEGORIZED | OR |
| FERRIPROX TWICE-A-DAY | OTHER NON-CATEGORIZED | OR |
| FIBRYGA | HEMOPHILIA | IV |
| FILSPARI | OTHER NON-CATEGORIZED | OR |
| FINGOLIMOD | MULTIPLE SCLEROSIS | OR |
| FIRAZYR | HEMATOLOGICAL | SC |
| FIRDAPSE | AUTOIMMUNE | OR |
| FOLLISTIM AQ | FERTILITY & PREGNANCY | SC |
| FORTEO | BONE DENSITY | SC |
| FOTIVDA | CANCER-ORAL | IV |
| FULPHILA | BLOOD MODIFIERS | SC |
| FYLNETRA | BLOOD MODIFIERS | SC |
| FYREMADEL | FERTILITY & PREGNANCY | SC |
| GALAFOLD | ENZYME DEFICIENCIES | OR |
| GANIRELIX ACETATE | FERTILITY & PREGNANCY | SC |
| GATTEX | GASTROINTESTINAL | SC |
| GAVRETO | CANCER-ORAL | OR |
| GEFITINIB | CANCER | OR |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|-----------------------|-------------------------|
| GENOTROPIN | GROWTH HORMONES | SC |
| GENOTROPIN MINIQUICK | GROWTH HORMONES | SC |
| GILENYA | MULTIPLE SCLEROSIS | OR |
| GILOTRIF | CANCER-ORAL | OR |
| GLASSIA | LUNG DISORDERS | IV |
| GLATIRAMER ACETATE | MULTIPLE SCLEROSIS | SC |
| GLATOPA | MULTIPLE SCLEROSIS | SC |
| GLEEVEC | CANCER-ORAL | OR |
| GLEOSTINE | CANCER-ORAL | OR |
| GOCOVRI | PARKINSON | OR |
| GONAL-F | FERTILITY & PREGNANCY | IJ |
| GONAL-F RFF | FERTILITY & PREGNANCY | SC |
| GONAL-F RFF REDIJECT | FERTILITY & PREGNANCY | SC |
| GRANIX | BLOOD MODIFIERS | SC |
| HADLIMA | AUTOIMMUNE | SC |
| HADLIMA PUSHTOUCH | AUTOIMMUNE | SC |
| HAEGARDA | HEMATOLOGICAL | SC |
| HARVONI | HEPATITIS C | OR |
| HEMLIBRA | HEMOPHILIA | SC |
| HEMOPIL M | HEMOPHILIA | IV |
| HETLIOZ | SLEEP DISORDERS | OR |
| HETLIOZ LQ | SLEEP DISORDERS | OR |
| HULIO | AUTOIMMUNE | SC |
| HUMATE-P | HEMOPHILIA | IV |
| HUMATROPE | GROWTH HORMONES | IJ |
| HUMIRA | AUTOIMMUNE | SC |
| HUMIRA PEDIATRIC CROHNS DISEASE STARTER PACK | AUTOIMMUNE | SC |
| HUMIRA PEN | AUTOIMMUNE | SC |
| HUMIRA PEN-CD/UC/HS STARTER | AUTOIMMUNE | SC |
| HUMIRA PEN-PEDIATRIC UC STARTER PACK | AUTOIMMUNE | SC |
| HUMIRA PEN-PS/UV STARTER | AUTOIMMUNE | SC |
| HYCANTIN | CANCER-ORAL | OR |
| HYRIMOZ | AUTOIMMUNE | SC |
| HYRIMOZ-CROHNS | AUTOIMMUNE | SC |
| HYRIMOZ-PEDITATRIC CROHNS | AUTOIMMUNE | SC |
| HYRIMOZ-PLAQUE PSORIASIS | AUTOIMMUNE | SC |
| IBRANCE | CANCER-ORAL | OR |
| ICATIBANT ACETATE | HEMATOLOGICAL | SC |
| ICLUSIG | CANCER-ORAL | OR |
| IDACIO | AUTOIMMUNE | SC |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|-----------------------|-------------------------|
| IDACIO CROHNS | AUTOIMMUNE | SC |
| IDACIO PLAQUE PSORIASIS | AUTOIMMUNE | SC |
| IDELVION | HEMOPHILIA | IV |
| IDHIFA | CANCER-ORAL | OR |
| IMATINIB MESYLATE | CANCER-ORAL | OR |
| IMBRUVICA | CANCER-ORAL | OR |
| IMCIVREE | LIFESTYLE | SC |
| INBRIJA | PARKINSON | IN |
| INCRELEX | GROWTH HORMONES | SC |
| INGREZZA | OTHER NON-CATEGORIZED | OR |
| INLYTA | CANCER-ORAL | OR |
| INQOVI | CANCER-ORAL | OR |
| INREBIC | CANCER-ORAL | OR |
| INTRON A | HEPATITIS C | IJ |
| IRESSA | CANCER-ORAL | OR |
| ISTURISA | ENDOCRINE | OR |
| IXINITY | HEMOPHILIA | IV |
| JADENU | OTHER NON-CATEGORIZED | OR |
| JADENU SPRINKLE | OTHER NON-CATEGORIZED | OR |
| JAKAFI | CANCER-ORAL | OR |
| JAVYGTOR | ENZYME DEFICIENCIES | OR |
| JAYPIRCA | CANCER | OR |
| JIVI | HEMOPHILIA | IV |
| JOENJA | OTHER NON-CATEGORIZED | OR |
| JUXTAPID | ANTHYPERLIPIDEMIC | OR |
| JYNARQUE | ENDOCRINE | OR |
| KALYDECO | CYSTIC FIBROSIS | OR |
| KESIMPTA | MULTIPLE SCLEROSIS | SC |
| KEVZARA | AUTOIMMUNE | SC |
| KINERET | AUTOIMMUNE | SC |
| KISQALI | CANCER-ORAL | OR |
| KISQALI FEMARA | CANCER-ORAL | OR |
| KITABIS PAK | CYSTIC FIBROSIS | IN |
| KOATE | HEMOPHILIA | IV |
| KOATE-DVI | HEMOPHILIA | IV |
| KOGENATE FS | HEMOPHILIA | IV |
| KORLYM | ENDOCRINE | OR |
| KOSELUGO | CANCER-ORAL | OR |
| KOVALTRY | HEMOPHILIA | IV |
| KRAZATI | CANCER | OR |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|------------------------|-------------------------|
| KUVAN | ENZYME DEFICIENCIES | OR |
| LAPATINIB DITOSYLATE | CANCER-ORAL | OR |
| LEDIPASVIR/SOFOSBUVIR | HEPATITIS C | OR |
| LENALIDOMIDE | CANCER | OR |
| LENVIMA | CANCER-ORAL | OR |
| LETAIRIS | PULMONARY HYPERTENSION | OR |
| LEUKERAN | CANCER-ORAL | OR |
| LEUKINE | BLOOD MODIFIERS | IJ |
| LEUPROLIDE ACETATE | OTHER NON-CATEGORIZED | IJ |
| LITFULO | AUTOIMMUNE | OR |
| LIVMARLI | OTHER NON-CATEGORIZED | OR |
| LIVTENCITY | ANTI-INFECTIVE | OR |
| LONSURF | CANCER-ORAL | OR |
| LORBRENA | CANCER-ORAL | OR |
| LUMAKRAS | CANCER | OR |
| LUMRYZ | SLEEP DISORDERS | OR |
| LUPKYNIS | IMMUNOSUPPRESSANTS | OR |
| LYNPARZA | CANCER-ORAL | OR |
| LYSODREN | CANCER-ORAL | OR |
| LYTGOBI | CANCER-ORAL | OR |
| MATULANE | CANCER-ORAL | OR |
| MAVENCLAD | MULTIPLE SCLEROSIS | OR |
| MAVYRET | HEPATITIS C | OR |
| MAYZENT | MULTIPLE SCLEROSIS | OR |
| MEKINIST | CANCER-ORAL | OR |
| MEKTOVI | CANCER-ORAL | OR |
| MELPHALAN | CANCER-ORAL | OR |
| MENOPUR | FERTILITY & PREGNANCY | SC |
| MIGLUSTAT | ENZYME DEFICIENCIES | OR |
| MONONINE | HEMOPHILIA | IV |
| MULPLETA | BLOOD MODIFIERS | OR |
| MYALEPT | ENZYME DEFICIENCIES | SC |
| MYCAPSSA | ENDOCRINE | OR |
| MYLERAN | CANCER-ORAL | OR |
| NATPARA | BONE DENSITY | SC |
| NERLYNX | CANCER-ORAL | OR |
| NEULASTA | BLOOD MODIFIERS | SC |
| NEULASTA ONPRO KIT | BLOOD MODIFIERS | SC |
| NEUPOGEN | BLOOD MODIFIERS | IJ |
| NEXAVAR | CANCER-ORAL | OR |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|------------------------|-------------------------|
| NGENLA | GROWTH HORMONES | SC |
| NILANDRON | CANCER-ORAL | OR |
| NILUTAMIDE | CANCER-ORAL | OR |
| NINLARO | CANCER-ORAL | OR |
| NITISINONE | ENZYME DEFICIENCIES | OR |
| NITYR | ENZYME DEFICIENCIES | OR |
| NIVESTYM | BLOOD MODIFIERS | IJ |
| NORDITROPIN FLEXPRO | GROWTH HORMONES | SC |
| NOURIANZ | PARKINSON | OR |
| NOVAREL | FERTILITY & PREGNANCY | IM |
| NOVOEIGHT | HEMOPHILIA | IV |
| NOVOSEVEN RT | HEMOPHILIA | IV |
| NUBEQA | CANCER-ORAL | OR |
| NUCALA | LUNG DISORDERS | SC |
| NUTROPIN AQ NUSPIN | GROWTH HORMONES | SC |
| NUWIQ | HEMOPHILIA | IV |
| NYVEPRIA | BLOOD MODIFIERS | SC |
| OBIZUR | HEMOPHILIA | IV |
| OCALIVA | GASTROINTESTINAL | OR |
| OCTREOTIDE ACETATE | ENDOCRINE | IJ |
| ODOMZO | CANCER-ORAL | OR |
| OFEV | LUNG DISORDERS | OR |
| OLUMIANT | AUTOIMMUNE | OR |
| OMNITROPE | GROWTH HORMONES | SC |
| ONUREG | CANCER-ORAL | OR |
| OPSUMIT | PULMONARY HYPERTENSION | OR |
| ORENCIA | AUTOIMMUNE | SC |
| ORENCIA CLICKJECT | AUTOIMMUNE | SC |
| ORENITRAM | PULMONARY HYPERTENSION | OR |
| ORFADIN | ENZYME DEFICIENCIES | OR |
| ORGOVYX | CANCER-ORAL | OR |
| ORKAMBI | CYSTIC FIBROSIS | OR |
| ORLADEYO | HEMATOLOGICAL | OR |
| ORSERDU | CANCER | OR |
| OTEZLA | AUTOIMMUNE | OR |
| IVIDREL | FERTILITY & PREGNANCY | SC |
| OXBRYTA | BLOOD MODIFIERS | OR |
| OXERVATE | OPHTHALMIC | OP |
| PALFORZIA | OTHER NON-CATEGORIZED | OR |
| PALYNZIQ | ENZYME DEFICIENCIES | SC |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.



Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|------------------------|-------------------------|
| PEGASYS | HEPATITIS C | SC |
| PEGASYS PROCLICK | HEPATITIS C | SC |
| PEMAZYRE | CANCER-ORAL | OR |
| PENICILLAMINE | OTHER NON-CATEGORIZED | OR |
| PHEBURANE | ENZYME DEFICIENCIES | OR |
| PHENYL BUTYRA | ENZYME DEFICIENCIES | OR |
| PIQRAY | CANCER-ORAL | OR |
| PIRFENIDONE | LUNG DISORDERS | OR |
| PLEGRIDY | MULTIPLE SCLEROSIS | SC |
| PLEGRIDY PEN | MULTIPLE SCLEROSIS | IM |
| POMALYST | CANCER-ORAL | OR |
| PONVORY | MULTIPLE SCLEROSIS | OR |
| PREGNYL W/DILUENT BENZYL ALCOHOL/NACL | FERTILITY & PREGNANCY | IM |
| PROCRIT | BLOOD MODIFIERS | IJ |
| PROCYSBI | OTHER NON-CATEGORIZED | OR |
| PROFILNINE | HEMOPHILIA | IV |
| PROMACTA | BLOOD MODIFIERS | OR |
| PULMOZYME | CYSTIC FIBROSIS | IN |
| PURIXAN | CANCER-ORAL | OR |
| PYRUKYND | HEMATOLOGICAL | OR |
| QINLOCK | CANCER-ORAL | OR |
| RADICAVA ORS | OTHER NON-CATEGORIZED | OR |
| RAVICTI | ENZYME DEFICIENCIES | OR |
| REBIF | MULTIPLE SCLEROSIS | SC |
| REBIF REBIDOSE | MULTIPLE SCLEROSIS | SC |
| REBIF REBIDOSE TITRATION PACK | MULTIPLE SCLEROSIS | SC |
| REBINYN | HEMOPHILIA | IV |
| RECOMBINATE | HEMOPHILIA | IV |
| RECORLEV | ENDOCRINE | OR |
| RELEUKO | BLOOD MODIFIERS | SC |
| RELEUKO | BLOOD MODIFIERS | IJ |
| RELYVRIO | OTHER NON-CATEGORIZED | OR |
| RETACRIT | BLOOD MODIFIERS | IJ |
| RETEVMO | CANCER-ORAL | OR |
| REVATIO | PULMONARY HYPERTENSION | OR |
| REVCOVI | ENZYME DEFICIENCIES | IM |
| REVLIMID | CANCER-ORAL | OR |
| REZLIDHIA | CANCER-ORAL | OR |
| REZUROCK | OTHER NON-CATEGORIZED | OR |
| RIASTAP | HEMOPHILIA | IV |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|------------------------|-------------------------|
| RIBAVIRIN | HEPATITIS C | OR |
| RINVOQ | AUTOIMMUNE | OR |
| RIXUBIS | HEMOPHILIA | IV |
| ROZLYTREK | CANCER-ORAL | OR |
| RUBRACA | CANCER-ORAL | OR |
| RUCONEST | HEMATOLOGICAL | IV |
| RUZURGI | AUTOIMMUNE | OR |
| RYDAPT | CANCER-ORAL | OR |
| SAIZEN | GROWTH HORMONES | IJ |
| SAIZENPREP RECONSTITUTIONKIT | GROWTH HORMONES | IJ |
| SAJAZIR | HEMATOLOGICAL | SC |
| SAMSCA | ENDOCRINE | OR |
| SANDOSTATIN | ENDOCRINE | IJ |
| SAPROPTERIN DIHYDROCHLORIDE | ENZYME DEFICIENCIES | OR |
| SCEMBLIX | CANCER | OR |
| SEROSTIM | GROWTH HORMONES | SC |
| SEVENFACT | HEMOPHILIA | IV |
| SIGNIFOR | ENDOCRINE | SC |
| SILDENAFIL CITRATE | PULMONARY HYPERTENSION | OR |
| SILIQ | AUTOIMMUNE | SC |
| SIMPONI | AUTOIMMUNE | SC |
| SKYCLARYS | OTHER NON-CATEGORIZED | OR |
| SKYRIZI | AUTOIMMUNE | SC |
| SKYRIZI PEN | AUTOIMMUNE | SC |
| SKYTROFA | GROWTH HORMONES | SC |
| SODIUM PHENYLBUTYRATE | ENZYME DEFICIENCIES | OR |
| SOFOSBUVIR/VELPATASVIR | HEPATITIS C | OR |
| SOGROYA | GROWTH HORMONES | SC |
| SOMAVERT | ENDOCRINE | SC |
| SORAFENIB TOSYLATE | CANCER | OR |
| SOTYKTU | AUTOIMMUNE | OR |
| SOVALDI | HEPATITIS C | OR |
| SPRYCEL | CANCER-ORAL | OR |
| STELARA | AUTOIMMUNE | SC |
| STIMUFEND | BLOOD MODIFIERS | SC |
| STIVARGA | CANCER-ORAL | OR |
| STRENSIQ | ENZYME DEFICIENCIES | SC |
| SUCRAID | ENZYME DEFICIENCIES | OR |
| SUNITINIB | CANCER | OR |
| SUTENT | CANCER-ORAL | OR |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|------------------------|-------------------------|
| SYMDEKO | CYSTIC FIBROSIS | OR |
| SYNAGIS | LUNG DISORDERS | IM |
| SYNAREL | ENDOCRINE | NA |
| SYNRIBO | CANCER | SC |
| SYPRINE | OTHER NON-CATEGORIZED | OR |
| TABLOID | CANCER-ORAL | OR |
| TABRECTA | CANCER-ORAL | OR |
| TADALAFIL | PULMONARY HYPERTENSION | OR |
| TADLIQ | PULMONARY HYPERTENSION | OR |
| TAFINLAR | CANCER-ORAL | OR |
| TAGRISSE | CANCER-ORAL | OR |
| TAKHZYRO | HEMATOLOGICAL | SC |
| TALTZ | AUTOIMMUNE | SC |
| TALZENNA | CANCER-ORAL | OR |
| TARCEVA | CANCER-ORAL | OR |
| TARGETIN | CANCER | EX |
| TARGETIN | CANCER-ORAL | OR |
| TASCENSO ODT | MULTIPLE SCLEROSIS | OR |
| TASIGNA | CANCER-ORAL | OR |
| TASIMELTEON | SLEEP DISORDERS | OR |
| TAVALISSE | BLOOD MODIFIERS | OR |
| TAVNEOS | HEMATOLOGICAL | OR |
| TAZVERIK | CANCER-ORAL | OR |
| TECFIDERA | MULTIPLE SCLEROSIS | OR |
| TEGSEDI | OTHER NON-CATEGORIZED | SC |
| TEMODAR | CANCER-ORAL | OR |
| TEMOZOLOMIDE | CANCER-ORAL | OR |
| TEPMETKO | CANCER-ORAL | OR |
| TERIFLUNOMID | MULTIPLE SCLEROSIS | OR |
| TERIPARATIDE | BONE DENSITY | SC |
| TETRABENAZINE | OTHER NON-CATEGORIZED | OR |
| TEZSPIRE | LUNG DISORDERS | SC |
| THALOMID | CANCER-ORAL | OR |
| TIBSOVO | CANCER-ORAL | OR |
| TOBI | CYSTIC FIBROSIS | IN |
| TOBI PODHALER | CYSTIC FIBROSIS | IN |
| TOBRAMYCIN | CYSTIC FIBROSIS | IN |
| TOLVAPTAN | ENDOCRINE | OR |
| TOREMIFENE CITRATE | CANCER-ORAL | OR |
| TRACLEER | PULMONARY HYPERTENSION | OR |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|------------------------|-------------------------|
| TREMFYA | AUTOIMMUNE | SC |
| TRETINOIN | CANCER-ORAL | OR |
| TRETTEN | HEMOPHILIA | IV |
| TRIENTINE HYDROCHLORIDE | OTHER NON-CATEGORIZED | OR |
| TRIKAFTA | CYSTIC FIBROSIS | OR |
| TRUSELTIQ | CANCER | OR |
| TUKYSA | CANCER-ORAL | OR |
| TURALIO | CANCER-ORAL | OR |
| TYKERB | CANCER-ORAL | OR |
| TYMLOS | BONE DENSITY | SC |
| TYVASO | PULMONARY HYPERTENSION | IN |
| TYVASO DPI | PULMONARY HYPERTENSION | IN |
| TYVASO REFILL | PULMONARY HYPERTENSION | IN |
| TYVASO STARTER | PULMONARY HYPERTENSION | IN |
| UDENYCA | BLOOD MODIFIERS | SC |
| UKONIQ | CANCER-ORAL | OR |
| UPTRAVI | PULMONARY HYPERTENSION | OR |
| UPTRAVI PACK | PULMONARY HYPERTENSION | OR |
| VALCHLOR | CANCER | EX |
| VANFLYTA | CANCER | OR |
| VENCLEXTA | CANCER-ORAL | OR |
| VENTAVIS | PULMONARY HYPERTENSION | IN |
| VERZENIO | CANCER-ORAL | OR |
| VIEKIRA PAK | HEPATITIS C | OR |
| VIJOICE | OTHER NON-CATEGORIZED | OR |
| VISTOGARD | OTHER NON-CATEGORIZED | OR |
| VITRAKVI | CANCER-ORAL | OR |
| VIZIMPRO | CANCER-ORAL | OR |
| VONJO | CANCER | OR |
| VONVENDI | HEMOPHILIA | IV |
| VOSEVI | HEPATITIS C | OR |
| VOTRIENT | CANCER-ORAL | OR |
| VOWST | GASTROINTESTINAL | OR |
| VOXZOGO | ENDOCRINE | SC |
| VUMERITY | MULTIPLE SCLEROSIS | OR |
| VYNDAMAX | OTHER NON-CATEGORIZED | OR |
| VYNDAQEL | OTHER NON-CATEGORIZED | OR |
| WAKIX | SLEEP DISORDERS | OR |
| WELIREG | CANCER | OR |
| WILATE | HEMOPHILIA | IV |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Pharmacy Benefit: | Drug Category | Route of Administration |
|--|-----------------------|-------------------------|
| XALKORI | CANCER-ORAL | OR |
| XELJANZ | AUTOIMMUNE | OR |
| XELJANZ XR | AUTOIMMUNE | OR |
| XELODA | CANCER-ORAL | OR |
| XENAZINE | OTHER NON-CATEGORIZED | OR |
| XERMELO | GASTROINTESTINAL | OR |
| XOLAIR | LUNG DISORDERS | SC |
| XOSPATA | CANCER-ORAL | OR |
| XPOVIO | CANCER-ORAL | OR |
| XTANDI | CANCER-ORAL | OR |
| XURIDEN | ENDOCRINE | OR |
| XYNTHA | HEMOPHILIA | IV |
| XYNTHA SOLOFUSE | HEMOPHILIA | IV |
| XYREM | SLEEP DISORDERS | OR |
| XYWAV | SLEEP DISORDERS | OR |
| YONSA | CANCER-ORAL | OR |
| YUFLYMA | AUTOIMMUNE | SC |
| YUSIMRY | AUTOIMMUNE | SC |
| ZARXIO | BLOOD MODIFIERS | IJ |
| ZAVESCA | ENZYME DEFICIENCIES | OR |
| ZEJULA | CANCER-ORAL | OR |
| ZELBORAF | CANCER-ORAL | OR |
| ZEPATIER | HEPATITIS C | OR |
| ZEPOSIA | MULTIPLE SCLEROSIS | OR |
| ZEPOSIA 7-DAY STARTER PACK | MULTIPLE SCLEROSIS | OR |
| ZIEXTENZO | BLOOD MODIFIERS | SC |
| ZOKINVY | OTHER NON-CATEGORIZED | OR |
| ZOLINZA | CANCER-ORAL | OR |
| ZOMACTON | GROWTH HORMONES | SC |
| ZORBIVE | GROWTH HORMONES | SC |
| ZYDELIG | CANCER-ORAL | OR |
| ZYKADIA | CANCER-ORAL | OR |
| ZYTIGA | CANCER-ORAL | OR |

Drugs Covered Under Your Medical Benefit:

Please note: Your plan benefits may have a prior authorization and/or added requirements that may need to be met before a drug can be considered for coverage. Your doctor can find request forms at bcbsil.com/provider. Your doctor can also call the number on your ID card with any questions about your benefits. To get the most out of your benefits, you should check if the pharmacy or provider used is in-network. You can call the number on your ID card for help.

| Drugs Covered Under Your Medical Benefit: | Drug Category | Route of Administration |
|---|---------------|-------------------------|
| ABECMA | CANCER | IV |
| ABRAXANE | CANCER | IV |
| ACTEMRA | AUTOIMMUNE | IV |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.



Specialty Drug Management List

| Drugs Covered Under Your Medical Benefit: | Drug Category | Route of Administration |
|---|-----------------------|-------------------------|
| ADAKVEO | BLOOD MODIFIERS | IV |
| ADCETRIS | CANCER | IV |
| ADRIAMYCIN | CANCER | IV |
| ADSTILADRIN | CANCER | IS |
| ADUHELM | OTHER NON-CATEGORIZED | IV |
| ALDURAZYME | ENZYME DEFICIENCIES | IV |
| ALFERON N | OTHER NON-CATEGORIZED | IJ |
| ALIMTA | CANCER | IV |
| ALIQOPA | CANCER | IV |
| ALKERAN | CANCER | IV |
| ALYMSYS | CANCER | IV |
| AMONDYS 45 | ENZYME DEFICIENCIES | IV |
| AMVUTTRA | OTHER NON-CATEGORIZED | SC |
| ARALAST NP | LUNG DISORDERS | IV |
| ARANESP ALBUMIN FREE | BLOOD MODIFIERS | IJ |
| ARRANON | CANCER | IV |
| ARSENIC TRIOXIDE | CANCER | IV |
| ASCENIV | IMMUNE GLOBULINS | IV |
| ASPARLAS | CANCER | IV |
| AVASTIN | CANCER | IV |
| AVSOLA | AUTOIMMUNE | IV |
| AZACITIDINE | CANCER | IJ |
| BELEODAQ | CANCER | IV |
| BELRAPZO | CANCER | IV |
| BENDAMUSTINE | CANCER | IV |
| BENDEKA | CANCER | IV |
| BENLYSTA | AUTOIMMUNE | IV |
| BEOVU | OPHTHALMIC | IZ |
| BESPONSА | CANCER | IV |
| BESREMI | CANCER | SC |
| BEYFORTUS | LUNG DISORDERS | IM |
| BICNU | CANCER | IV |
| BIVIGAM | IMMUNE GLOBULINS | IV |
| BLENREP | CANCER | IV |
| BLINCYTO | CANCER | IV |
| BORTEZOMIB | CANCER | IV |
| BORTEZOMIB | CANCER | IV |
| BOTOX | OTHER NON-CATEGORIZED | IJ |
| BREYANZI | CANCER | IV |
| BRINEURA | ENZYME DEFICIENCIES | VE |
| BRIUMVI | MULTIPLE SCLEROSIS | IV |
| BYOOVIZ | OPHTHALMIC | IZ |
| CABLIV | BLOOD MODIFIERS | IJ |
| CAMCEVI | CANCER | SC |
| CARMUSTINE | CANCER | IV |
| CARVYKTI | CANCER | IV |
| CEREZYME | ENZYME DEFICIENCIES | IV |
| CIMERLI | OPHTHALMIC | IZ |
| CIMZIA | AUTOIMMUNE | SC |
| CINQAIR | LUNG DISORDERS | IV |
| CINRYZE | HEMATOLOGICAL | IV |
| CLADRIBINE | CANCER | IV |
| CLOFARABINE | CANCER | IV |
| CLOLAR | CANCER | IV |
| COLUMVI | CANCER | IV |
| COSELA | CANCER | IV |
| COSMEGEN | CANCER | IV |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.



Specialty Drug Management List

| Drugs Covered Under Your Medical Benefit: | Drug Category | Route of Administration |
|---|------------------------|-------------------------|
| CRYSVITA | ENDOCRINE | SC |
| CUTAQUIG | IMMUNE GLOBULINS | SC |
| CUVITRU | IMMUNE GLOBULINS | SC |
| CYRAMZA | CANCER | IV |
| DACOGEN | CANCER | IV |
| DACTINOMYCIN | CANCER | IV |
| DANYELZA | CANCER | IV |
| DARZALEX | CANCER | IV |
| DARZALEX | CANCER | SC |
| DAUNORUBICIN | CANCER | IV |
| DAXXIFY | OTHER NON-CATEGORIZED | IM |
| DECITABINE | CANCER | IV |
| DOCETAXEL | CANCER | IV |
| DOXIL | CANCER | IV |
| DOXORUBICIN | CANCER | IV |
| DURYSTA | OPHTHALMIC | IO |
| DYSPORT | OTHER NON-CATEGORIZED | IM |
| ELAHERE | CANCER | IV |
| ELAPRASE | ENZYME DEFICIENCIES | IV |
| ELELYSO | ENZYME DEFICIENCIES | IV |
| ELEVIDYS | OTHER NON-CATEGORIZED | IV |
| ELFABRIO | ENZYME DEFICIENCIES | IV |
| ELIGARD | OTHER NON-CATEGORIZED | SC |
| ELITEK | CANCER | IV |
| EMPLICITI | CANCER | IV |
| ENHERTU | CANCER | IV |
| ENJAYMO | HEMATOLOGICAL | IV |
| ENTYVIO | AUTOIMMUNE | IV |
| EPKINLY | CANCER | SC |
| EPOGEN | BLOOD MODIFIERS | IJ |
| EPOPROSTENOL SODIUM | PULMONARY HYPERTENSION | IV |
| ERBITUX | CANCER | IV |
| EUFLEXXA | VISCO SUPPLEMENTS | IX |
| EVENITY | BONE DENSITY | SC |
| EVKEEZA | ANTIHYPERLIPIDEMIC | IV |
| EVOMELA | CANCER | IV |
| EXONDYS 51 | ENZYME DEFICIENCIES | IV |
| EYLEA | OPHTHALMIC | IZ |
| FABRAZYME | ENZYME DEFICIENCIES | IV |
| FASENRA | LUNG DISORDERS | SC |
| FASLODEX | CANCER | IM |
| FENSOLVI | ENDOCRINE | SC |
| FIBRYGA | HEMOPHILIA | IV |
| FIRMAGON | CANCER | SC |
| FLEBOGAMMA DIF | IMMUNE GLOBULINS | IV |
| FLOLAN | PULMONARY HYPERTENSION | IV |
| FOLOTYN | CANCER | IV |
| FULPHILA | BLOOD MODIFIERS | SC |
| FULVESTRANT | CANCER | IM |
| FYARRO | CANCER | IV |
| FYLNETRA | BLOOD MODIFIERS | SC |
| GAMASTAN | IMMUNE GLOBULINS | IM |
| GAMIFANT | OTHER NON-CATEGORIZED | IV |
| GAMMAGARD LIQUID | IMMUNE GLOBULINS | IJ |
| GAMMAGARD S/D IGA LESS THAN 1MCG/ML | IMMUNE GLOBULINS | IV |
| GAMMAKED | IMMUNE GLOBULINS | IJ |
| GAMMAPLEX | IMMUNE GLOBULINS | IV |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Medical Benefit: | Drug Category | Route of Administration |
|---|-----------------------|-------------------------|
| GAMUNEX-C | IMMUNE GLOBULINS | IJ |
| GAZYVA | CANCER | IV |
| GEL-ONE | VISCO SUPPLEMENTS | IX |
| GENVISC 850 | VISCO SUPPLEMENTS | IX |
| GIVLAARI | BLOOD MODIFIERS | SC |
| GRANIX | BLOOD MODIFIERS | SC |
| HALAVEN | CANCER | IV |
| HEMGENIX | HEMOPHILIA | IV |
| HERCEP HYLEC | CANCER | SC |
| HERCEPTIN | CANCER | IV |
| HERZUMA | CANCER | IV |
| HIZENTRA | IMMUNE GLOBULINS | SC |
| HYALGAN | VISCO SUPPLEMENTS | IX |
| HYCANTIN | CANCER | IV |
| HYDROXYPROGESTERONE CAPROATE | CANCER | IM |
| HYQVIA | IMMUNE GLOBULINS | SC |
| IBANDRONATE SODIUM | BONE DENSITY | IV |
| IDAMYCIN PFS | CANCER | IV |
| ILARIS | AUTOIMMUNE | SC |
| ILUMYA | AUTOIMMUNE | SC |
| ILUVIEN | OTHER NON-CATEGORIZED | IZ |
| IMFINZI | CANCER | IV |
| IMJUDO | CANCER | IV |
| INFLECTRA | AUTOIMMUNE | IV |
| INFLIXIMAB | AUTOIMMUNE | IV |
| ISTODAX OVR | CANCER | IV |
| IXEMPRA KIT | CANCER | IV |
| JELMYTO | CANCER | UL |
| JEMPERLI | CANCER | IV |
| JEVTANA | CANCER | IV |
| KADCYLA | CANCER | IV |
| KALBITOR | HEMATOLOGICAL | SC |
| KANJINTI | CANCER | IV |
| KANUMA | ENZYME DEFICIENCIES | IV |
| KEYTRUDA | CANCER | IV |
| KHAPZORY | CANCER | IV |
| KIMMTRAK | CANCER | IV |
| KRYSTEXXA | OTHER NON-CATEGORIZED | IV |
| KYMRIAH | CANCER | IV |
| KYPROLIS | CANCER | IV |
| LAMZEDE | ENZYME DEFICIENCIES | IV |
| LANREOTIDE | ENDOCRINE | SC |
| LEMTRADA | MULTIPLE SCLEROSIS | IV |
| LEQEMBI | OTHER NON-CATEGORIZED | IV |
| LEUKINE | BLOOD MODIFIERS | IJ |
| LUCENTIS | OPHTHALMIC | IZ |
| LUMIZYME | ENZYME DEFICIENCIES | IV |
| LUNSUMIO | CANCER | IV |
| LUPRON DEPOT | CANCER | IM |
| LUPRON DEPOT-PED | ENDOCRINE | IM |
| LUXTURNA | OPHTHALMIC | IO |
| MARGENZA | CANCER | IV |
| MARQIBO | CANCER | IV |
| MELPHALAN | CANCER | IV |
| MEPSEVII | ENZYME DEFICIENCIES | IV |
| MITOMYCIN | CANCER | IV |
| MITOMYCIN | CANCER | IS |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.

Specialty Drug Management List

| Drugs Covered Under Your Medical Benefit: | Drug Category | Route of Administration |
|---|------------------------|-------------------------|
| MONJUVI | CANCER | IV |
| MOZOBIL | BLOOD MODIFIERS | SC |
| MVASI | CANCER | IV |
| MYOBLOC | OTHER NON-CATEGORIZED | IM |
| NAGLAZYME | ENZYME DEFICIENCIES | IV |
| NELARABINE | CANCER | IV |
| NEULASTA | BLOOD MODIFIERS | SC |
| NEUPOGEN | BLOOD MODIFIERS | IJ |
| NEXVIAZYME | ENZYME DEFICIENCIES | IV |
| NIPENT | CANCER | IV |
| NIVESTYM | BLOOD MODIFIERS | IJ |
| NPLATE | BLOOD MODIFIERS | SC |
| NUCALA | LUNG DISORDERS | SC |
| NULIBRY | ENZYME DEFICIENCIES | IV |
| NULOJIX | IMMUNOSUPPRESSANTS | IV |
| NYVEPRIA | BLOOD MODIFIERS | SC |
| OCREVUS | MULTIPLE SCLEROSIS | IV |
| OCTAGAM | IMMUNE GLOBULINS | IV |
| OGIVRI | CANCER | IV |
| OMISIRGE | CANCER | IV |
| ONCASPAR | CANCER | IJ |
| ONIVYDE | CANCER | IV |
| ONPATTRO | OTHER NON-CATEGORIZED | IV |
| ONTRUZANT | CANCER | IV |
| OPDIVO | CANCER | IV |
| OPDUALAG | CANCER | IV |
| ORENCIA | AUTOIMMUNE | IV |
| OXLUMO | OTHER NON-CATEGORIZED | SC |
| PACLITAXEL | CANCER | IV |
| PADCEV | CANCER | IV |
| PANZYGA | IMMUNE GLOBULINS | IV |
| PEDMARK | CANCER | IV |
| PEMETREXED | CANCER | IV |
| PEMFEXY | CANCER | IV |
| PEPAXTO | CANCER | IV |
| PHESGO | CANCER | SC |
| PHOTOFRIN | CANCER | IV |
| PLERIXAFOR | BLOOD MODIFIERS | SC |
| POLIVY | CANCER | IV |
| PORTRAZZA | CANCER | IV |
| PRALATREXATE | CANCER | IV |
| PRIVIGEN | IMMUNE GLOBULINS | IV |
| PROCRIT | BLOOD MODIFIERS | IJ |
| PROLASTIN-C | LUNG DISORDERS | IV |
| PROLEUKIN | CANCER | IV |
| PROLIA | BONE DENSITY | SC |
| PROVENGE | CANCER | IV |
| QALSODY | OTHER NON-CATEGORIZED | IT |
| RADICAVA | OTHER NON-CATEGORIZED | IV |
| REBLOZYL | BLOOD MODIFIERS | SC |
| REBYOTA | GASTROINTESTINAL | RE |
| RECLAST | BONE DENSITY | IV |
| RELEUKO | BLOOD MODIFIERS | SC |
| RELEUKO | BLOOD MODIFIERS | IJ |
| REMICADE | AUTOIMMUNE | IV |
| REMODULIN | PULMONARY HYPERTENSION | IJ |
| RENFLEXIS | AUTOIMMUNE | IV |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.



Specialty Drug Management List

| Drugs Covered Under Your Medical Benefit: | Drug Category | Route of Administration |
|---|------------------------|-------------------------|
| RETACRIT | BLOOD MODIFIERS | IJ |
| REVATIO | PULMONARY HYPERTENSION | IV |
| RIABNI | CANCER | IV |
| RIASTAP | HEMOPHILIA | IV |
| RITUXAN | CANCER | IV |
| RITUXAN HYCELA | CANCER | SC |
| ROCTAVIAN | HEMOPHILIA | IV |
| ROLVEDON | BLOOD MODIFIERS | SC |
| ROMIDEPSIN | CANCER | IV |
| RUXIENCE | CANCER | IV |
| RYBREVANT | CANCER | IV |
| RYLAZE | CANCER | IM |
| RYPLAZIM | HEMATOLOGICAL | IV |
| RYSTIGGO | OTHER NON-CATEGORIZED | SC |
| SANDOSTATIN LAR DEPOT | ENDOCRINE | IM |
| SAPHNELO | AUTOIMMUNE | IV |
| SCENESSE | OTHER NON-CATEGORIZED | SC |
| SILDENAFIL | PULMONARY HYPERTENSION | IV |
| SIMPONI ARIA | AUTOIMMUNE | IV |
| SKYRIZI | AUTOIMMUNE | IV |
| SKYSONA | OTHER NON-CATEGORIZED | IV |
| SOLIRIS | HEMATOLOGICAL | IV |
| SOMATULINE DEPOT | ENDOCRINE | SC |
| SPEVIGO | AUTOIMMUNE | IV |
| SPINRAZA | OTHER NON-CATEGORIZED | IT |
| SPRAVATO | OTHER NON-CATEGORIZED | NA |
| STELARA | AUTOIMMUNE | IV |
| STIMUFEND | BLOOD MODIFIERS | SC |
| SUPARTZ FX | VISCO SUPPLEMENTS | IX |
| SUPPRELIN LA | ENDOCRINE | SC |
| SUSVIMO | OPHTHALMIC | IZ |
| SYFOVRE | OPHTHALMIC | IZ |
| SYLVANT | CANCER | IV |
| SYNAGIS | LUNG DISORDERS | IM |
| SYNVISC | VISCO SUPPLEMENTS | IX |
| SYNVISC ONE | VISCO SUPPLEMENTS | IX |
| TALVEY | CANCER | SC |
| TECARTUS | CANCER | IV |
| TECENTRIQ | CANCER | IV |
| TECVAYLI | CANCER | SC |
| TEMSIROLIMUS | CANCER | IV |
| TEPADINA | CANCER | IJ |
| TEPEZZA | ENDOCRINE | IV |
| TEZSPIRE | LUNG DISORDERS | SC |
| THIOTEPA | CANCER | IJ |
| THROMBATE III | OTHER NON-CATEGORIZED | IV |
| THYROGEN | OTHER NON-CATEGORIZED | IM |
| TICE BCG | CANCER | IS |
| TIVDAK | CANCER | IV |
| TOPOTECAN | CANCER | IV |
| TORISEL | CANCER | IV |
| TRAZIMERA | CANCER | IV |
| TREANDA | CANCER | IV |
| TRELSTAR MIXJECT | CANCER | IM |
| TREPROSTINIL | PULMONARY HYPERTENSION | IJ |
| TRISENOX | CANCER | IV |
| TRIVISC | VISCO SUPPLEMENTS | IX |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.



Specialty Drug Management List

| Drugs Covered Under Your Medical Benefit: | Drug Category | Route of Administration |
|---|------------------------|-------------------------|
| TRUXIMA | CANCER | IV |
| TYSABRI | MULTIPLE SCLEROSIS | IV |
| TZIELD | DIABETES | IV |
| UDENYCA | BLOOD MODIFIERS | SC |
| ULTOMIRIS | HEMATOLOGICAL | IV |
| UNITUXIN | CANCER | IV |
| UPLIZNA | OTHER NON-CATEGORIZED | IV |
| UPTRAVI | PULMONARY HYPERTENSION | IV |
| VABYSMO | OPHTHALMIC | IZ |
| VALRUBICIN | CANCER | IS |
| VALSTAR | CANCER | IS |
| VECTIBIX | CANCER | IV |
| VEGZELMA | CANCER | IV |
| VELCADE | CANCER | IJ |
| VELETRI | PULMONARY HYPERTENSION | IV |
| VIDAZA | CANCER | IJ |
| VILTEPSO | ENZYME DEFICIENCIES | IV |
| VIMIZIM | ENZYME DEFICIENCIES | IV |
| VISCO-3 | VISCO SUPPLEMENTS | IX |
| VISUDYNE | OPHTHALMIC | IV |
| VIVIMUSTA | CANCER | IV |
| VPRIV | ENZYME DEFICIENCIES | IV |
| VYJUVEK | DERMATOLOGICS | EX |
| VYONDYS 53 | ENZYME DEFICIENCIES | IV |
| VYVGART | OTHER NON-CATEGORIZED | IV |
| VYXEOS | CANCER | IV |
| XEMBIFY | IMMUNE GLOBULINS | SC |
| XENPOZYME | ENZYME DEFICIENCIES | IV |
| XEOMIN | OTHER NON-CATEGORIZED | IM |
| XGEVA | BONE DENSITY | SC |
| XIAFLEX | OTHER NON-CATEGORIZED | IJ |
| XOLAIR | LUNG DISORDERS | SC |
| YERVOY | CANCER | IV |
| YESCARTA | CANCER | IV |
| YONDELIS | CANCER | IV |
| ZALTRAP | CANCER | IV |
| ZANOSAR | CANCER | IV |
| ZARXIO | BLOOD MODIFIERS | IJ |
| ZEMAIRA | LUNG DISORDERS | IV |
| ZEPZELCA | CANCER | IV |
| ZIEXTENZO | BLOOD MODIFIERS | SC |
| ZIRABEV | CANCER | IV |
| ZOLADEX | CANCER | SC |
| ZOLEDRONIC ACID | BONE DENSITY | IV |
| ZOLGENSMA | OTHER NON-CATEGORIZED | IV |
| ZYNLONTA | CANCER | IV |
| ZYNTEGLO | BLOOD MODIFIERS | IV |
| ZYNYZ | CANCER | IV |

Route of Administration key: CO=Combination, EX=External, IJ=Injection, IM=Intramuscular, IN=Inhalation, IO=Intraocular, IT=Intrathecal, IV=Intravenous, IX=Intraarticular, IZ=Intravitreal, OP=Ophthalmic, OR=Oral, SC=Subcutaneous

This list is subject to change without notice. Product names are the property of their respective owners.

The relationship between Blue Cross and Blue Shield of Illinois and the specialty pharmacies is that of independent contractors. Blue Cross and Blue Shield of Illinois contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. Blue Cross and Blue Shield of Illinois, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield of Association.



If you, or someone you are helping, have questions, you have the right to get help and information in your language at no cost. To talk to an interpreter, call 855-710-6984.

| | |
|--------------------------|---|
| Español Spanish | Si usted o alguien a quien usted está ayudando tiene preguntas, tiene derecho a obtener ayuda e información en su idioma sin costo alguno. Para hablar con un intérprete, llame al 855-710-6984. |
| العربية Arabic | إن كان لديك أو لدى شخص تساعد أسئلة، فلديك الحق في الحصول على المساعدة والمعلومات الضرورية بلغتك من دون أية تكلفة. للتحدث مع مترجم نوري، اتصل على الرقم 855-710-6984. |
| 繁體中文 Chinese | 如果您，或您正在協助的對象，對此有疑問，您有權利免費以您的母語獲得幫助和訊息。洽詢一位翻譯員，請撥電話 號碼 855-710-6984。 |
| Français French | Si vous, ou quelqu'un que vous êtes en train d'aider, avez des questions, vous avez le droit d'obtenir de l'aide et l'information dans votre langue à aucun coût. Pour parler à un interprète, appelez 855-710-6984. |
| Deutsch German | Falls Sie oder jemand, dem Sie helfen, Fragen haben, haben Sie das Recht, kostenlose Hilfe und Informationen in Ihrer Sprache zu erhalten. Um mit einem Dolmetscher zu sprechen, rufen Sie bitte die Nummer 855-710-6984 an. |
| ગુજરાતી Gujara ti | જો તમને અથવા તમને મદદ કરી રાહી હોય એવી કોઈ બીજી ચક્તિને એસ.બી.એમ. કાર્યક્રમ બાબતે પ્રશ્ન હોય, તો તમને વિના ખર્ચે, તમારી ભાષામાં મદદ અને માહિતી મેળવવાનો હક છે. દાખલામાં સાથે વાત કરવા માટે આ નંબર 855-710-6984 પર કોલ કરો. |
| हिंदी Hindi | यदि आपके, या आप जिसकी सहायता कर रहे ह उसके, प्रश्न ह, तो आपको अपनी भाषा में निःशुल्क सहायता और जानकारी प्राप्त करने का अधिकार है। किसी अनुवादक से बात करने के लिए 855-710-6984 पर कॉल करें। |
| Italiano Italian | Se tu o qualcuno che stai aiutando avete domande, hai il diritto di ottenere aiuto e informazioni nella tua lingua gratuitamente. Per parlare con un interprete, puoi chiamare il numero 855-710-6984. |
| 한국어 Korean | 만약 귀하 또는 귀하가 돕는 사람이 질문이 있다면 귀하는 무료로 그러한 도움과 정보를 귀하의 언어로 받을 수 있는 권리가 있습니다. 통역사가 필요하시면 855-710-6984 로 전화하십시오. |
| Diné Navajo | T'11 ni, 47 doodago [a'da b7k1 an1n7lwo'7g77, na'7d7[kidgo, ts'7d1 bee n1 ah00ti'i' t'11 n77k'e n7k1 a'doolwo[d00 b7na'7d7[kid7g77 bee ni[h odoonih. Ata'dahalne'7g77 bich'8' hod77lnih kwe'4 855-710-6984. |
| فارسی Persian | اگر شما، یا کسی که شما به او کمک می کنید، سوالاتی داشته باشید، حق این را دارید که به زبان خود، به طور رایگان کمک و اطلاعات دریافت نمایید. جهت گفتگو با یک مترجم شفاهی، با شماره 855-710-6984 تماس حاصل نمایید. |
| Polski Polish | Jeśli Ty lub osoba, której pomagasz, macie jakiegokolwiek pytania, macie prawo do uzyskania bezpłatnej informacji i pomocy we własnym języku. Aby porozmawiać z tłumaczem, zadzwoń pod numer 855-710-6984. |
| Русский Russian | Если у вас или человека, которому вы помогаете, возникли вопросы, у вас есть право на бесплатную помощь и информацию, предоставленную на вашем языке. Чтобы связаться с переводчиком, позвоните по телефону 855-710-6984. |
| Tagalog Tagalog | Kung ikaw, o ang isang taong iyong tinutulungan ay may mga tanong, may karapatan kang makakuha ng tulong at impormasyon sa iyong wika nang walang bayad. Upang makipag-usap sa isang tagasalin-wika, tumawag sa 855-710-6984. |
| اردو Urdu | اگر آپ کو، یا کسی ایسے فرد کو جس کی آپ مدد کر رہے ہیں، کوئی سوال درپیش ہے تو، آپ کو اپنی زبان میں مفت مدد اور معلومات حاصل کرنے کا حق ہے۔ مترجم سے بات کرنے کے لیے، 855-710-6984 پر کال کریں۔ |
| Tiếng Việt Vietnamese | Nếu quý vị, hoặc người mà quý vị giúp đỡ, có câu hỏi, thì quý vị có quyền được giúp đỡ và nhận thông tin bằng ngôn ngữ của mình miễn phí. Để nói chuyện với một thông dịch viên, gọi 855-710-6984. |



Health care coverage is important for everyone.

We provide free communication aids and services for anyone with a disability or who needs language assistance. We do not discriminate on the basis of race, color, national origin, sex, gender identity, age, sexual orientation, health status or disability.

To receive language or communication assistance free of charge, please call us at 855-710-6984.

If you believe we have failed to provide a service, or think we have discriminated in another way, contact us to file a grievance.

Office of Civil Rights Coordinator
300 E. Randolph St.
35th Floor
Chicago, Illinois 60601

Phone: 855-664-7270 (voicemail)
TTY/TDD: 855-661-6965
Fax: 855-661-6960
Email: CivilRightsCoordinator@hcsc.net

You may file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, at:

U.S. Dept. of Health & Human Services
200 Independence Avenue SW
Room 509F, HHH Building 1019
Washington, DC 20201

Phone: 800-368-1019
TTY/TDD: 800-537-7697
Complaint Portal: <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>
Complaint Forms: <http://www.hhs.gov/ocr/office/file/index.html>